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Abstract 
Neurodegenerative disorders are characterised by progressive loss of neuronal functions. Of the proposed 
mechanisms, excitotoxicity, mediated by prolonged glutamate activation and calcium overload, is prominent. 
NGP1-01, a polycyclic cage amine, and tricyclo[6.2.1.02,7]undec-9-ene-3,6-dione have been shown to display 
calcium-modulating properties. In this study, we synthesised structurally-related 4-oxatricyclo[5.2.1.02,6]dec-8-
ene-3,5-dione as the base scaffold, and incorporated various functional moieties through aminolysis, to afford 
a series of imide derivatives. All final compounds were obtained in yields between 47-97% and their structures 
were confirmed by NMR, IR and MS. These structurally-related derivatives could potentially act as 
neuroprotective agents. Additionally, their synthetic versatilities could make them precursors, as lead 
compounds, to potential pharmacologically-active agents. 
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Introduction 
Neurodegenerative disorders are diseases characterised by persistent and progressive loss of neuronal 
function that eventually lead to neuronal death and reduction of sensory, motor, cognition and memory 
functions.1,2 These disorders include Parkinson’s disease (PD), Alzheimer’s disease (AD), progressive 
supranuclear palsy, amyotrophic lateral sclerosis (ALS) and Huntington disease.3 These multifactorial diseases 
not only share many common features, such as a late appearance in life, neuronal loss and synaptic 
abnormalities, but also share common molecular mechanisms that include excitotoxicity, mitochondrial 
dysfunction, apoptosis, oxidative stress and impaired protein homeostasis.4 Of the proposed mechanisms, the 
influence of excitotoxicity is prominent. In excitotoxicty, extracellular glutamate levels are elevated to such an 
extent that they over-activate ionotropic receptors, N-methyl-D-aspartate (NMDA) receptors, and associated 
voltage-gated calcIum channels (VGCC) in particluar. This results in the increase of intracellular calcium ions, 
thus disrupting calcium homeostasis.5-9 Due to the sensitivity of neurons towards intracellular calcium-ion 
concentration, disruption of calcium homeostasis can lead to destructive consequences, such as damage to 
cell dendrites or neuronal cell death, in part, by activating calpain, a cysteine protease, that degrades a variety 
of substrates, such as cytoskeletal proteins, membrane receptors and metabolic enzymes.10-13 Therefore, 
molecules capable of modulating calcium influx via the NMDA receptor and/or VGCC could provide protection 
against calcium overload mediated by prolonged glutamate activity. MK-801 has been shown to 
uncompetitively block NMDA receptors, but is marked by undesirable psychotomimetic side effects such as 
hallucination, psychosis, dysphoria and amnesia. This makes it unsuitable for therapeutic purpose.14 
To date, no drug is available to stop the neurodegenerative process. Adamatanes such as amantadine and 
memantine (Figure 1), however, have been shown to offer symptomatic relief in patients with PD and AD, 
respectively, and has subsequently been approved by the FDA for these purposes. 
 
 
Figure 1.  Polycyclic cage-like uncompetitive NMDA receptor antagonists 
 
The activities and clinical tolerabilities of the adamantanes are attributed to their ability to 
uncompetitively block NMDA receptors while displaying minimal adverse effects.15-18 Over the past few 
decades, a number of structurally-related polycyclic cage amines have been synthesised.19-26 A very good 
example is NGP1-01, a multifuctional neuroprotective agent that displayed dual attenuation of calcium entry 
in neuronal cells by blocking NMDA receptors and VGCCs. It exhibits neuroprotective properties and a good 
safety profile as demonstrated by several studies.27-31 The need for more structurallly-related scaffolds with 
similar effects and good safety profiles, that could potentially halt the degenerative process of neuronal cells, 
is, thus, clear.  
A series of tricycloundecene derivatives that exhibit calcium-inhibitiory effects via the NMDA receptor and 
VGCC have been reported (Figure 2).26 
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Figure 2.  Tricyclo[6.2.1.02,7]undec-9-ene-3,6-dione- (1) and 4-oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (2)  
The significant activity observed for tricyclo[6.2.1.02,7]undec-9-ene-3,6-dione (1) was attributed to its 
structural similarities to MK-801 and the adamantanes (Figure 1). In the synthesis of 1, the cycloaddition 
reaction between p-benzoquinone and monomerised cyclopentadiene yielded an intermediate which was 
subsequently selectively reduced by zinc to afford the desired compound in fair yield (Figure 3).25,26  
 
 
Figure 3.  Synthesis of compound 1. Reagents and conditions: (i) toluene, hexane:ethyl acetate (4:1), 0 ˚C, 
3.5 h; (ii) glacial CH3COOH, zinc powder, rt, 30 mins.26 
 
Cycloaddition reactions are common, and found to be useful in the formation of most norbornene-derived 
molecules, particularly the polycyclic-cage scaffolds.32-38 These molecules are prominent scaffolds in improving 
the pharmacokinetic and pharmacological properties of active pharmaceutical substances.19 Moreover, they 
display wide reactivity as substrates for various functional moeities, and, as such, are very useful and highly 
desirable synthetic intermediates in the field of organic and organometallic chemistry.39-42 The desire to 
continously expand on existing lead molecules with neuroprotective potential justify the need for additional  
structurally-related analogues.  
In the present study, we explored similar cycloaddition reactions to synthesise 4-oxatricyclo[5.2.1.02,6]dec-
8-ene-3,5-dione (2), which was used as the base scaffold. To this base structure, a number of aliphatic, 
heterocylic or aromatic functionalities were incorporated through aminolysis to synthesise a series of 4-
oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione derivatives (3-13, Figure 4).  
 
 
 
Figure 4. Synthetic route of compounds 2-13. Reagents and conditions: i) toluene, reflux, 1.5 h; ii) toluene, 
trimethylamine, reflux, 10-24 h. Percentage yields are shown in brackets. 
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This series of compounds are structurally related to NGP1-01, MK-801, the adamantanes and 1, and we 
hypothesise that these derivatives would exhibit similar or improved calcium-modulating effects and 
significant neuroprotective properties.They may also serve as lead scaffolds in the development of 
neuroprotective agents. 
 
Results and Discussion 
Synthesis and structural elucidation 
Under reflux conditions, the Diels-Alder reaction between maleic anhydride and cyclopentadiene afforded 
compound 2, an open cage-like 4-oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione molecule,43 which was used to 
obtain compounds 3-13 in moderate-to-high yields (see Figure 4). The aminolysis of 2 with benzylamine 
afforded compound 3 and the byproduct 4 (dibenzylamide moiety; Figure 5) in yields of 83% and 6%, 
respectively.  
 
 
 
Figure 5.  Formation of compounds 4 and 10: a) Compound 4 was obtained as a by-product from the synthesis 
of 3; b) Compound 10 was obtained as a precipitate from the reaction between compound 2 and 
ethylenediamine in the synthesis of 9. Percentage yields are shown in brackets. 
The presence of the norbornene scaffold in compound 4 justifies its inclusion in the series. Moreover, the 
replacement of the furandione moiety with a dibenzylamine moiety provides scope for additional structure-
activity relationships within this series. Compounds 9 and 10 were obtained under similar reaction conditions 
involving compound 2 and ethylenediamine; however, they differed in their work-up. Extraction using ethyl 
acetate afforded 9 in a yield of 90%, while precipitation from ice-cold methanol produced compound 10 (10%; 
Figure 5). Compound 10 was included in the series due to its bis-4-oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione 
structure. Amongst the diamines (9-13), the reaction of compound 2 and N,N-dimethylethylenediamine 
produced the highest yield, 96% (13). This was due to the dimethyl substitution of one of the amines which 
limited byproduct formation. 
The structures of compounds 2-13 were characterised by their respective 1H, 13C, IR and HRMS spectra. In 
the IR spectra, the characteristic C=O signals were observed in the 1654-1766 cm-1 region for all the 
compounds (2-13). The appearance of absorption bands at around 1654 cm-1 (C=O) and 3304 cm-1 (N-H) 
confirms the amide moieties observed in 4. The presence of characteristic medium and broad signals for 
aliphatic primary amines in the 3372-3386 cm-1 region indicate mono-substitution of the diamines, which 
correspond to the structure of compound 9, 11 and 12. The appearance of a strong, sharp absorption band at 
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3265 cm-1 supported the presence of an aliphatic alkyne in the structure of 6. In the 1H NMR spectra, the 
bridge protons resonate in the δ = 1.55-1.81 and δ = 1.45-1.59 ppm range for all compounds. The aromatic 
protons of 3 and 4 were identified as multiplets in the δ = 7.18-7.31 ppm region with integrations of five and 
ten hydrogens, respectively. The aromatic protons of 8 were observed as a doublet of doublets (δ = 7.20-7.24 
ppm; J 15.9, 7.6 Hz), a triplet (δ = 6.93-6.97 ppm; J 7.4 Hz) and a doublet (δ = 6.75-6.76 ppm; J 7.7 Hz). The 
piperidinyl protons of 5 were observed as a triplet (δ = 3.07-3.10 ppm; 4H) and two multiplets (δ = 1.61-1.67 
ppm, 4H; δ = 1.37-1.43 ppm, 2H). In compound 6, the doublet (δ 4.09 ppm; J 2.5 Hz; 2H) and triplet (δ 2.13 
ppm; J 2.5 Hz; 1H) signals were assigned to the CH2 and CH groups of the propargyl conjugate. The appearance 
of multiplet (δ = 1.41-1.51 ppm; 2H) and triplet (δ = 0.84-0.87 ppm; J 7.4 Hz; 3H) signals in the spectra of 7 
indicates the presence of a propyl moiety. The presence of a triplet at δ = 2.72-2.75 ppm (J 6.4 Hz; 2H), and a 
doublet at δ = 3.40 ppm (J 6.4 Hz; 2H), confirms the successful incorporation of the diamine conjugate (9). The 
disappearance of signals in the 2.00-3.00 ppm region suggest disubstitution of the diamine to afford 10. Due 
to the symmetrical nature of the carbons adjacent to the nitrogen groups, the CH2 protons were observed 
downfield as a multiplet (δ = 3.64 ppm; 4H). In comparison to 9, the appearance of a singlet (δ = 2.20 ppm; 6H) 
indicates the presence of the dimethyl substituent as observed in 13. The appearance of a doublet of triplet 
signal and a doublet of doublet signal at δ = 1.59-1.64 ppm (J 6.7, 4.8 Hz; 1H) and δ = 1.65-1.71 ppm (J 13.7, 
5.1 Hz; 1H), respectively, indicates the presence of an additional CH2 group when compared to compound 9, 
thus, confirming the formation of the diaminopropane conjugate (11). In comparison to 11, the additional CH2 
group of 12 was observed as a multiplet at δ = 1.34-1.41 ppm with an integration of two protons, thus, 
confirming the presence of a diaminobutane conjugate. In general, all of the protons of compounds 9-13 were 
accounted for, and assigned according to their respective spectra. In the 13C NMR spectra, the characteristic 
signals for carbonyl and aromatic moieties were observed in the δ = 171-178 ppm and δ = 115-138 ppm 
regions, respectively. The carbon signals in the spectra of all compounds (2-13) were identified, and they 
corresponded to their proposed structures. The HRMS showed the respective molecular ion peaks that 
correspond to the empirical formula of each compound. 
Reaction conditions that led to the formation of 2 and 3 afforded the respective endo-isomers. The 
physical characteristics of these isomers correspond to those reported in the literature.43-46 Similar reaction 
conditions were used in the synthesis of the remaining compounds (5-13), and their respective isomers were 
derived in a similar manner. 
NMDA and VGCC studies 
The abilities of compounds 2-13 to block calcium influx via the NMDA receptor and VGCCs were evaluated 
using neuroblastoma cells, and the fluorescent ratiometric calcium indicator FURA-2AM, as previously 
described in detail by our group.21,22,26 The compounds were found to exhibit calcium modulating abilities at 
the NMDA receptor and VGCC within a similar activity range as NGP1-01 and 1 at a 10 µM concentration. 
These initial promising biological findings have now led to the further exploration of their calcium modulating 
effect, neuroprotective abilities and toxicity profiles.  
 
Conclusions 
4-Oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione derivatives (2-13) were successfully synthesised and 
characterised. All compounds, except the byproducts 4 (6.3%) and 10 (12.3%), were obtained in considerable 
yields of 47-96%. We established that the derivatives (2-13) have significant calcium-modulating effect and 
Arkivoc 2020, v, 0-0  Egunlusi, A. O. et al. 
 Page 5  ©AUTHOR(S) 
could potentially act as neuroprotective agents. Additionally, they could serve as versatile synthetic precursors 
for potential neuroprotective agents or pharmaceutically-active scaffolds. 
Experimental Section 
General. Unless otherwise specified, all reagents were obtained from Merck (St Louis, MO, USA) and Sigma-
Aldrich® (Darmstadt, Germany) and used without further purification unless specified. Solvents used for 
reactions and chromatography were purchased from various commercial sources and dried using standard 
methods. The structures of the desired compounds were characterised and confirmed by means of nuclear 
magnetic resonance (NMR), Fourier transform infrared (FT-IR) and mass spectrometry (MS) techniques. In the 
NMR spectroscopy, 1H, 13C and distortionless enhancement of polarisation transfer (DEPT) analysis were 
performed for structural elucidation. Using a Bruker Avance III HD spectrometer, the 1H spectra were obtained 
at 400 MHz while the 13C spectra were obtained at 100 MHz. Tetramethylsilane (TMS) and deuterated solvent 
peaks were used as internal standards. The multiplicities of NMR signals are expressed as: s, singlet; bs, broad 
singlet; d, doublet; dd, doublet of doublets; dt, doublet of triplets; t, triplet; m, multiplet. High-resolution mass 
spectra (HRMS) were recorded on a Waters API Q-TOF Ultima spectrometer using the electrospray ionization 
technique. Infrared spectra were obtained on a Perkin Elmer Spectrum 400 FT-IR/FT-NIR spectrometer, fitted 
with a diamond attenuated total reflectance (ATR) attachment. The melting points were determined using a 
Stuart SMP-300 melting point apparatus and capillary tubes.  
Chemistry 
(1R,2S,6R,7S)-4-Oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (2). To a solution of maleic anhydride (10 g, 100 
mmol) in toluene (100 ml), monomerised cyclopentadiene (7 g, 105.90 mmol) was slowly added and refluxed. 
After 1.5 hours, the mixture was allowed to cool to room temperature and concentrated in vacuo to form a 
crude white product. The product was purified by re-crystallisation in methanol to afford a white crystalline 
material (8.04 g, 49%). The NMR data and melting point of compound 2 correspond to those reported in the 
literature.43,44,46 Physical characteristics: mp 163-165 °C (Lit. 164 °C).44 FT-IR (ATR): ѵmax (cm-1) = 1840, 1766, 
1229, 1088, 901, 733. 1H-NMR (400 MHz, CDCl3): δ 6.31 (t, J 1.6 Hz, 2H), 3.58-3.57 (dd, J 3.0, 1.7 Hz, 2H), 3.51-
3.50 (dd, J 2.9, 1.6 Hz, 2H), 1.80-1.77 (dt, J 9.0, 1.5 Hz. 1H), 1.58-1.56 (d, J 9.0 Hz, 1H). 13C-NMR (100 MHz, 
CDCl3) and DEPT-135: δ 171.29 (C=O), 135.55 (C=C), 52.76 (CH2), 47.08 (CH), 46.13 (CH). 
General procedure for the synthesis of 3-13.   
The appropriate amine ((benzylamine (3, 1 mmol), 1-aminopiperidine (5, 1 mmol), propargylamine (6, 2.6 
mmol), propylamine (7, 3.9 mmol), phenylhydrazine (8, 4 mmol), ethylenediamine (9, 2.7 mmol), 1,3-
diaminopropane (11, 1.4 mmol), 1,4-diaminobutane (12, 3 mmol) or N,N-dimethylethylenediamine (13, 2.5 
mmol)) were reacted with compound 2 (1 mmol) in toluene (100 ml) under reflux conditions for 10-24 hours 
to afford compounds 3-13, respectively.  
(1R,2S,6R,7S)-4-Benzyl-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (3) and N,N’-dibenzylbicyclo[2.2.1]-hept-
5-ene-2,3-dicarboxamide (4). The crude yellow oil formed was purified using silica gel column 
chromatography with 25% hexane in ethyl acetate as mobile phase to afford 3 and impurity 4 as white 
powders (3: 1.28 g, 83%; 4: 0.13 g, 6%.). The NMR data of compound 3 correspond to those reported in the 
literature.45 Physical characteristics (3): mp 87-89 °C. FT-IR (ATR): ѵmax (cm-1) = 2875, 1689, 1391, 1336, 1169, 
901, 702. 1H-NMR (400 MHz, CDCl3): δ 7.31-7.22 (m, 5H), 5.89 (t, J 1.6 Hz, 2H), 4.48 (s, 2H), 3.37-3.36 (dd, J 2.7, 
1.6 Hz, 2H), 3.25-3.24 (dd, J 2.8, 1.5 Hz, 2H), 1.70-1.67 (dt, J 8.8, 1.4 Hz, 1H), 1.50-1.52 (d, J 8.8 Hz, 1H). 13C-
NMR (100 MHz, CDCl3) and DEPT-135: δ 177.44 (C=O), 136.03 (Ar-C), 134.34 (C=C), 128.92 (Ar-C), 128.39 (Ar-
C), 127.76 (Ar-C), 52.14 (CH2), 45.76 (CH), 45.02 (CH), 42.03 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for 
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C16H15NO2 254.1176; Found 254.1177. Physical characteristics (4): mp 141-143 °C. FT-IR (ATR): ѵmax (cm-1) = 
3304, 2977, 1654, 1532, 1454, 1227, 1028, 908, 698. 1H-NMR (400 MHz, CDCl3): δ 7.31-7.18 (m, 10H), 6.33 (m, 
2H), 4.25-4.14 (m, 4H), 3.23 (m, 2H), 3.10 (m, 2H), 1.44 (d, J 8.5, 1H), 1.24 (d, J 9.2 Hz, 1H). 13C-NMR (100 MHz, 
CDCl3) and DEPT-135: δ 172.80 (C=O), 138.21 (Ar-C), 135.76 (C=C), 128.62 (Ar-C), 127.73 (Ar-C), 127.34 (Ar-C), 
52.04 (CH), 49.98 (CH2), 47.35 (CH), 43.52 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for C23H24N2O2 361.1910; 
Found 361.1913. 
(1R,2S,6R,7S)-4-(1-Piperidyl)-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (5). After evaporating the solvent in 
vacuo, the final product was crystalized from methanol as white crystals (0.70 g, 47%). Physical characteristics: 
mp 163-166 °C. FT-IR (ATR): ѵmax (cm-1) = 2996, 2938, 1708, 1452, 1339, 1285, 1185, 845, 718. 1H-NMR (400 
MHz, CDCl3): δ 6.12-6.11 (t, J = 1.6 Hz, 2H), 3.39 (m, 2H), 3.12-3.11 (dd, J 2.8, 1.5 Hz, 2H), 3.10-3.07 (t, J 5.4 Hz, 
4H), 1.70-1.67 (dt, J 8.8, 1.6 Hz, 1H), 1.67-1.61 (m, 4H), 1.48-1.45 (d, J 8.8 Hz, 1H), 1.43-1.37 (m, 2H). 13C-NMR 
(100 MHz, CDCl3) and DEPT-135: δ 176.48 (C=O), 134.45 (C=C), 52.22 (CH2), 51.55 (CH2), 45.17 (CH), 43.46 (CH), 
25.89 (CH2), 23.06 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for C14H18N2O2 247.1441; Found 247.1446. 
(1R,2S,6R,7S)-4-Prop-2-ynyl-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (6). The crude yellow oil formed was 
purified by recrystallization in a mixture of hexane and ethyl acetate to afford yellow crystals (0.93 g, 76%). 
Physical characteristics: mp 99-101 °C. FT-IR (ATR): ѵmax (cm-1) = 3265, 1759, 1703, 1530, 1423, 1383, 1323, 
1175, 1120, 1090, 951, 906, 845, 715, 668. 1H-NMR (400 MHz, CDCl3): δ 6.11-6.10 (t, J 1.6 Hz, 2H), 4.09-4.08 
(d, J 2.5 Hz, 2H), 3.42 (m, 2H), 3.30-3.29 (dd, J 2.8, 1.5 Hz, 2H), 2.14-2.12 (t, J 2.5 Hz, 1H), 1.75-1.72 (dt, J 8.8,1.5 
Hz, 1H), 1.55-1.53 (d, J 8.8 Hz, 1H). 13C-NMR (100 MHz, CDCl3) and DEPT-135: δ 176.38 (C=O), 134.46 (C=C), 
70.97 (C), 52.14 (CH2), 45.86 (CH), 45.17 (CH), 27.21 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for 
C12H11NO2 202.0863; Found 202.0866. 
(1R,2S,6R,7S)-4-propyl-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (7). The crude residue was purified by 
crystallization from hexane to afford the final product as white crystals (1.19 g, 95%). Physical characteristics: 
mp 70-72 °C. FT-IR (ATR): ѵmax (cm-1) = 3267, 2965, 1763, 1683, 1550, 1467, 1337, 1301, 1198, 1138, 1015, 874, 
737, 666. 1H-NMR (400 MHz, CDCl3): δ 6.10 (t, J 1.5 Hz, 2H), 3.39 (m, 2H), 3.31-3.28 (t, J 7.4 Hz, 2H), 3.25-3.24 
(dd, J 2.8, 1.5 Hz, 2H), 1.74-1.72 (dt, J 8.7, 1.5 Hz, 1H), 1.55-1.53 (d, J 8.8 Hz, 1H), 1.51-1.41 (m, 2H), 0.87-0.84 
(t, J 7.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3) and DEPT-135: δ 177.84 (C=O), 134.43 (C=C), 52.23 (CH2), 45.73 
(CH), 44.90 (CH), 40.05 (CH2), 21.16 (CH2), 11.38 (CH3). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for 
C12H15NO2 206.1176; Found 206.1179. 
(1R,2S,6R,7S)-4-Anilino-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (8). The crude white powder was purified 
by precipitation from ice-cold methanol to produce a white powder (0.76 g, 49%). Physical characteristics: mp 
191-194°C. FT-IR (ATR): νmax (cm-1) = 3282, 2955, 1767, 1703, 1601, 1497, 1381, 1295, 1184, 1138, 1056, 980, 
845, 727, 696. 1H-NMR (400 MHz, CDCl3): δ 7.24-7.20 (dd, J 15.9, 7.6 Hz, 2H), 6.97-6.93 (t, J 7.4 Hz, 1H), 6.76-
6.75 (d, J 7.7 Hz, 2H), 6.22-6.21 (t, J 1.6 Hz, 2H), 6.01 (s, NH), 3.49 (m, 2H), 3.36-3.35 (dd, J 2.7, 1.5 Hz, 2H), 
1.81-1.78 (dt, J 8.9, 1.5 Hz, 1H), 1.59-1.57 (d, J 8.9 Hz, 1H). 13C-NMR (100 MHz, CDCl3) and DEPT-135: δ 175.32 
(C=O), 145.13 (Ar-C), 135.03 (C=C), 129.15 (Ar-C), 122.57 (Ar-C), 115.03 (Ar-C), 52.14 (CH2), 44.99 (CH), 44.12 
(CH). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for C15H14N2O2 255.1128; Found 255.1133. 
(1R,2S,6R,7S)-4-(2-Aminoethyl)-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (9) and 3,5-dioxo-4-azatricyclo-
[5.2.1.02,6]dec-8-en-4-yl]ethyl]-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (10). The crude mixture was 
stirred in ethyl acetate (100 ml) at room temperature for 30 minutes and filtered. The filtrate was 
concentrated in vacuo to afford a yellow oil that solidified at room temperature rendering compound 9 (1.13 
g, 90%). The precipitate formed was isolated and re-crystallised from ice-cold methanol to afford 10 as white 
crystals (0.21 g, 10%). Physical characteristics (9): FT-IR (ATR): ѵmax (cm-1) = 3379, 2946, 1762, 1687, 1549, 
1490, 1440, 1400, 1335, 1156, 1051, 842, 778, 724. 1H-NMR (400 MHz, CDCl3): δ 6.12-6.11 (t, J 1.7 Hz, 2H), 
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3.40 (d, J 6.4 Hz, 2H), 3.38 (m, 2H), 3.27-3.26 (dd, J 2.8, 1.5 Hz, 2H), 2.75-2.72 (t, J 6.4 Hz, 2H) 1.75-1.72 (dt, J 
8.8, 1.5 Hz, 1H), 1.55-1.53 (d, J 8.8 Hz, 1H). 13C-NMR (100 MHz, CDCl3) and DEPT-135: δ 177.98 (C=O), 134.57 
(C=C), 52.31 (CH2), 45.81 (CH), 44.92 (CH), 41.67 (CH2), 40.11 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for 
C11H14N2O2 207.1128; Found 207.1135. Physical characteristics (10): mp 262-265 °C. FT-IR (ATR): ѵmax (cm-1) = 
2998, 1759, 1690, 1435, 1379, 1336, 1154, 1029, 975, 842, 780, 716. 1H-NMR (400 MHz, CDCl3): δ 6.05 (m, 4H), 
3.46 (m, 4H), 3.33(m, 4H), 3.23-3.22 (dd, J 2.8, 1.5 Hz, 4H), 1.72-1.70 (d, J 8.7 Hz, 2H), 1.52-1.50 (d, J 8.7 Hz, 
1H). 13C-NMR (100 MHz, CDCl3) and DEPT-135: δ 177.70 (C=O), 134.45 (C=C), 52.14 (CH2), 45.96 (CH), 44.67 
(CH), 36.37 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for C20H20N2O4 353.1496; Found 353.1497. 
(1R,2S,6R,7S)-4-(3-Aminopropyl)-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (11) The crude yellow mixture 
formed was purified using silica gel column chromatography with 90% ethyl acetate in methanol as mobile 
phase to afford a light-yellow oil (0.68 g, 51%). Physical characteristics: FT-IR (ATR): ѵmax (cm-1) = 3372, 2944, 
2868, 1729, 1658, 1474, 1406, 1339, 1299, 1251, 1193, 1127, 977, 918, 840, 747, 717. 1H-NMR (400 MHz, 
CD3OD): δ 6.03-6.01 (dd, J 5.6, 2.7 Hz, 1H), 5.99-5.97 (dd, J 5.6, 2.7 Hz, 1H), 3.33-3.30 (m, 2H), 3.29-3.26 (m, 
2H), 3.23-3.22 (dd, J 3.2, 1.6 Hz, 2H), 3.17-3.16 (m, 1H), 3.15-3.12 (dd, J 7.8, 4.6 Hz, 1H), 1.71-1.65 (dd, J 13.7, 
5.1 Hz, 1H), 1.64-1.59 (dt, J 6.7, 4.8 Hz, 1H) 1.58-1.55 (dt, J 8.6, 1.6 Hz, 1H), 1.49-1.47 (d, J 8.6 Hz, 1H). 13C-NMR 
(100 MHz, CD3OD) and DEPT-135: δ 176.9 (C=O), 159.23 (C=O), 134.28 (C=C), 134.03 (C=C), 50.83 (CH2), 45.56 
(CH), 45.50 (CH), 44.42 (CH), 43.79 (CH), 43.73 (CH2), 37.30 (CH2), 18.72 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ 
calcd. for C12H16N2O2 221.1285; Found 221.1288. 
(1R,2S,6R,7S)-4-(4-Aminobutyl)-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (12). The crude yellow product 
formed was purified using silica gel column chromatography with ethyl acetate/ammonia/methanol (69:1:30) 
as mobile phase to afford a light-yellow oil (0.80 g, 56%). Physical characteristics: FT-IR (ATR): ѵmax (cm-1) = 
3387, 2941, 2869, 1760, 1684, 1567, 1436, 1337, 1217, 1146, 1024, 896, 843, 723. 1H-NMR (400 MHz, CDCl3): 
δ 6.08 (t, J 1.6 Hz, 2H), 3.37 (m, 2H), 3.34-3.30 (t, J 7.1 Hz, 2H), 3.23-3.22 (dd, J 2.7, 1.4 Hz, 2H), 2.68-2.65 (t, J 
6.9 Hz, 2H), 1.73-1.70 (dt, J 8.8, 1.4 Hz, 1H), 1.53-1.51 (d, J 8.0 Hz, 1H), 1.48-1.42 (m, 2H) 1.41-1.34 (m, 2H). 
13C-NMR (100 MHz, CDCl3) and DEPT-135: δ 177.76 (C=O), 134.23 (C=C), 52.24 (CH2), 45.74 (CH), 44.90 (CH), 
41.61 (CH2), 38.15 (CH2), 30.88 (CH2), 25.14 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ calcd. for 
C13H18N2O2 235.1441; Found 235.1443. 
(1R,2S,6R,7S)-4-[2-(Dimethylamino)ethyl]-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione (13). The crude 
residue was purified using silica gel column chromatography with 90% ethyl acetate as mobile phase to afford 
a white oil that solidified at room temperature to give the final product as a white powder (1.39 g, 97%). 
Physical characteristics: mp 83-85 °C. FT-IR (ATR): ѵmax (cm-1) = 3456, 2971, 2789, 1739, 1687, 1355, 1229, 
1152, 1046, 1001, 950, 914, 843, 778, 722. 1H-NMR (400 MHz, CDCl3): δ 6.06 (t, J 1.6 Hz, 2H), 3.44-3.41 (t, J 6.9 
Hz, 2H), 3.35 (m, 2H), 3.24-3.23 (dd, J 2.8, 1.5 Hz, 2H), 2.32-2.29 (t, J 6.9 Hz, 2H), 2.20 (s, 6H), 1.71-1.69 (dt, J 
8.7, 1.4 Hz, 1H), 1.52-1.50 (d, J 8.7 Hz, 2H). 13C-NMR (100 MHz, CDCl3) and DEPT-135: δ 177.70 (C=O), 134.37 
(C=C), 56.26 (CH2), 52.09 (CH2), 45.77 (CH), 45.37 (CH3), 44.85 (CH), 36.19 (CH2). HRMS (ESI/TOF) m/z: [M+H]+ 
calcd. for C13H18N2O2 235.1441; Found 235.1442. 
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